Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
By G. von Minckwitz, A. du Bois, Marcus Schmidt, N. Maass, T. Čufer, F. D. de Jongh, E. Maartense, C. Zielinski, M. Kaufmann, W. Bauer and 8 more. Journal of Clinical Oncology, 2009
642 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/38eb3c555e30b479e91212e2e6492fe5e4cdc390
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. (2010, background): “domized study demonstrating trastuzumab efficacy beyond progression.(8) JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 28 NUMBER 7 MARCH 1 2010”
- ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, background): “Clinical experience had suggested that trastuzumab-refractory tumors remained dependent on HER2 as continuing trastuzumab in new treatment regimens beyond progression to trastuzumab demonstrated clinical benefit (von Minckwitz et al., 2009).”